Product Description
Adafosbuvir (AL 335), a monophosphate prodrug, is being developed by Alios BioPharma (a subsidiary of Johnson & Johnson) for the treatment of hepatitis C virus (HCV) infections. Adafosbuvir acts a uridine-based nucleotide analogue polymerase inhibitor. (Sourced from: https://newdrugapprovals.org/tag/alios-biopharma/)
Mechanisms of Action: HCV-NS5B Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Johnson & Johnson
Company Location: NEW BRUNSWICK NJ 08933
Company CEO: Joaquin Duato
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Hepatitis C, Chronic|Hepatitis A
Phase 1: Hepatitis A|Hepatitis C, Chronic|Other|Healthy Volunteers|Kidney Diseases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| JapicCTI-163468 | P2 |
Completed |
Hepatitis C, Chronic |
2018-06-30 |
|
| AL-335-604 | P2 |
Completed |
Hepatitis C, Chronic |
2018-05-11 |
|
| AL-335-604 | P2 |
Completed |
Hepatitis C, Chronic |
2018-05-11 |
|
| 2016-002845-46 | P2 |
Completed |
Hepatitis C, Chronic |
2018-05-11 |
|
| CR108264 | P2 |
Completed |
Hepatitis C, Chronic|Hepatitis A |
2018-05-07 |
22% |
| CR108264 | P2 |
Completed |
Hepatitis C, Chronic|Hepatitis A |
2018-05-07 |
22% |